# Early Phase Clinical Research Support

> **NIH NIH P30** · UNIVERSITY OF ARIZONA · 2021 · $470,272

## Abstract

Project Summary / Abstract: Early Phase Clinical Research Support (EPCRS) 
The goal of the EPCRS Program is to provide critical support to the UACC Early Phase Program (EPP), in 
which Early Phase trials with the potential for high impact are developed and initiated to provide access to 
Early Phase research to patients and high-risk persons from the UACC catchment area. The EPP provides 
support for short-term Pilot (pre-Phase I) and Phase I clinical research studies originating from UACC 
investigators whose outcomes form the basis of an application for later phase studies through external 
competitive grants, national group, or industry-sponsored trial support. The Phase I Multi-Disciplinary Team 
(MDT) manages the overall portfolio of Early Phase research and constitutes the oversight committee that 
reviews Early Phase research concepts. High priority is given to innovative investigator-initiated trials that 
focus on initial Early Phase testing of a novel candidate agent, device, or biomarker for the detection, 
prevention, or treatment of cancer; priority is given to those trials for which the preclinical development of 
translational science was performed by UACC researchers. The Phase I MDT is comprised of physicians and 
scientists with expertise in cancer therapeutics and chemoprevention trial development and basic scientists 
who conduct translational laboratory-based research. Early Phase concepts are further triaged by the Clinical 
Research Oversight Council, which ultimately ranks trials for EPCRS funding support. The EPP trial 
development and clinical operations are comprised of a Protocol Writer, Contract Specialist, Regulatory 
Specialists, Clinical Research Specialists, Research Nurses, a Research Program Manager, a dedicated Early 
Phase Nurse Navigator, and a Pharmacokinetics Technician. The EPP has conducted a wide range of studies 
that have led to novel scientific discoveries and to the further development of these discoveries in the context 
of later phase trials supported by NIH grant mechanisms and industry sponsored trials. A large portfolio of 
novel Early Phase IITs is currently in development and supported by UACC funding. These trials will utilize a 
broad range of analytic methods, including genomics, proteomics, metabolomics, analytical chemistry, cancer 
imaging, and bioinformatics.

## Key facts

- **NIH application ID:** 10407103
- **Project number:** 3P30CA023074-40S6
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** WILLIAM G CANCE
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $470,272
- **Award type:** 3
- **Project period:** 1997-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10407103

## Citation

> US National Institutes of Health, RePORTER application 10407103, Early Phase Clinical Research Support (3P30CA023074-40S6). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10407103. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*